NCT07562152Phase 3Recruiting

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2028-06Estimated

Enrollment · participants510Estimated

Source updated2026-09-25Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Adenocarcinoma Metastatic; Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatic Adenocarcinoma

Treatments or interventions studied

AtebimetinibDrug
GnPDrug
mGnPDrug

Primary outcomes · main study measures

measure: Overall Survival; description: The OS of participants with atebimetinib in combination with mGnP versus GnP; timeFrame: Up to approximately 2 years

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history